

Appendix

Contents:

Supplementary List 1: List of principle investigators and ethics approvals by site, page 2

Supplementary Table 1: Study hospitals resources in ABC-DO, page 3

Supplementary Table 2: Sociodemographic profile of the study sample, page 4

Supplementary Table 3: Tumour profile of the study sample, page 5

Supplementary Table 4: TNM stage and its ascertainment, page 6

Supplementary Table 5: Surgical management for localised vs locally advanced tumours, page 7

Supplementary Figure 1: Venn diagrams of treatment regimens for localised vs locally advanced tumours, page 8

Supplementary Figure 2: Indicated vs. initiated surgery, chemotherapy and endocrine therapy per population group, page 9

Supplementary Figure 3: Individual treatment journeys per population group, page 10

Supplementary List 1: List of principle investigators and ethics approvals by site

Site/Institution (ethics approval)	PI	No. non-metastatic breast cancer patients included in the present analysis
University of Witwatersrand (M150345), Gauteng, South Africa	H. Cubasch, M. Joffe	578
Ministry of Health and Social Services of Namibia (17/3/3)	A. Zietsman	400
Abia State University Teaching Hospital (ABSUTH), Nigeria	C. Adisa, S. Offiah	110
Federal Medical Centre Owerri, Nigeria	A. Anele	182
Uganda National Council for Science and Technology (HS 1588), Uganda	M. Galudande	296
University of Zambia Biomedical Research Ethics Committee (004-08-15), Zambia	G. Parham	150
IARC (IEC13-19, IEC15-18)	V. McCormack	-
LSHTM (6459)	I. dos Santos Silva	-

Supplementary Table 1: Public tertiary study/recruitment hospitals in ABC-DO and available diagnostic and therapeutic resources

Country	Namibia	Nigeria	South Africa	Uganda	Zambia ^A
Location	Windhoek Central Hospital, AB May Oncology Centre	FMC Owerri, ABSUTH and Maranatha clinic, Aba	Chris Hani Baragwanath Academic Hospital, Soweto	Mulago hospital, Uganda Cancer Institute, Kampala	Cancer Diseases Hospital, Lusaka & Kabwe Hospital
Catchment population	National (to 1000 km)	Local	Soweto ± 50 km	National (to 600 km)	provincial and national
Health facility: System level	Tertiary Public	NA Public	Tertiary Public	Tertiary Public	Sec/Tertiary Public
Health facility: Sector					
Treatment costs	Free/minimal	Out-of-pocket	Free/minimal	Out-of-pocket	Out-of-pocket
Diagnostic work-up					
Imaging					
Ultrasound	Free	5,000NGN / 12 USD	Free	Out-of-pocket	K50 / 3 USD
Mammography	Free	10,000NGN /24 USD	Free	Out-of-pocket	K250 / 15 USD
Computer Tomography	Free	80,000NGN /195 USD	Free	Out-of-pocket	K900 / 56 USD
MRI	Free	120,000NGN /290 USD	Free	Out-of-pocket	K1800 / 112 USD
Bone Scan	Free	4,000NGN /10 USD	Free	Not available	Not Available
Biopsy	Free	40,000NGN / 100 USD	Free	free	K320 / 20 USD
Fine Needle Aspiration Cytology	Free	40,000NGN / 100 USD	Free	Free	K300 / 19 USD
Receptor testing		42,000NGN / 100 USD			Not available
Oestrogen/Progesterone	Free	X	Free	Out-of-pocket	Not available
HER2	Free	X	Free	Out-of-pocket	Not available
FISH	Free	X	Free	Out-of-pocket	Not available
Full blood tests	Free	3,000NGN / 7 USD	Free	free	K50 / 3 USD
ECG	Free	32,000NGN / 80 USD	Free	Out-of-pocket	K50 / 3 USD
Treatment					
Surgery					
Mastectomy	Free	120,000NGN / 290 USD	Free	free	free
Lumpectomy / Wide local excision	Free	45,000NGN / 110 USD	Free	Free	free
Systemic therapy					
Pre-chemotherapy tests	Free	~15,000NGN / 35 USD	Free	free	free
Chemotherapy drugs					
Cyclophosphamide	Free	~125,000NGN / 300 USD	Free	Free when in stock	free
Anthracycline	Free	~ 136,000NGN / 330 USD	Free	Free when in stock	free
5-Fluorouracil	Free	~10,000NGN /24 USD	Free	Free when in stock	free
Methotrexate	Free	~60,000NGN / 144 USD	Free	Free when in stock	free
Taxane	Free	~ 80,000NGN /190 USD	Free	Free when in stock	free
Platinum-based drugs	Free	--	Free	Free when in stock	free
Hormonal therapy					
Tamoxifen	Free	~14,000NGN / 35 USD	Free	Free when in stock	free when in stock
Aromatase inhibitors	Free	~ 84,000NGN /200 USD	Free	Out-of-pocket	free
Trastuzumab	Free	~4.8M NGN / 11550 USD	Free	Out-of-pocket	free
Radiotherapy machine		~500,000NGN / 1200 USD			free
Cobalt 60	Free	X	Free ^B	Out-of-pocket	free
Linear accelerator	Free	--	Free ^B	Out-of-pocket	free

^A Mammography is not being done at CDH or UTH. Patients have to have it done privately. IHCs : ER, PR, HER2, Ki67 are not done in the public institutions. Patients have to have it done privately at their own cost. With the introduction of the National Health Insurance Management authority (NHIMA), all the investigation listed in the table above (except IHCs) are done without any additional cost to the patients. The patient pays monthly subscription of K60 to access NHIMA services. NHIMA also [provides contrast for imaging through its accredited pharmacies. Hormone Therapy is free when available in the hospital. When out of stock in the hospital, patients collect from NHIMA accredited pharmacies;

^B Not operational on repeated occasions in Uganda

Supplementary Table 2: Sociodemographic profile of non-metastatic women with known stage information in the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort

	Namibia black	Namibia non-black	Nigeria	South Africa black	South Africa non-black	Uganda	Zambia	Total
Number of women	N=309	N=91	N=292	N=544	N=34	N=296	N=150	N=1716
	N (column %) unless stated otherwise							
Age in years (mean (SD))	52.2 (15.1)	57.3 (12.2)	49.2 (12.2)	54.8 (14.6)	53.5 (15.0)	48.1 (12.5)	51.7 (14.1)	52 (14.1)
Symptom duration, months (median (IQR))	5.7 (2.1-14.9)	1.4 (0.4-4.8)	5.1 (2.7-11.8)	-	-	11.7 (5.8-24.7)	8.3 (2.8-20.3)	7.0 (2.5-17.6)
Socioeconomic position ^A								
Low	132 (42.7)	0 (0)	130 (44.5)	279 (51.3)	13 (38.2)	167 (56.4)	48 (32.0)	769 (44.8)
Medium	110 (35.6)	37 (40.7)	121 (41.4)	171 (31.4)	7 (20.6)	64 (21.6)	53 (35.3)	563 (32.8)
High	67 (21.7)	54 (59.3)	41 (14.0)	91 (16.7)	14 (41.2)	65 (22.0)	49 (32.7)	381 (22.2)
Education								
tertiary	49 (15.9)	36 (39.6)	103 (35.3)	105 (19.3)	12 (35.3)	39 (13.2)	35 (23.3)	379 (22.1)
<tertiary	260 (84.1)	55 (60.4)	189 (64.7)	370 (68.0)	20 (58.8)	257 (86.8)	115 (76.7)	1266 (73.8)
missing	0 (0.0)	0 (0)	0 (0.0)	69 (12.7)	2 (5.9)	0 (0.0)	0 (0.0)	71 (4.1)
Relationship ^B								
Married	104 (33.7)	53 (58.2)	201 (68.8)	205 (37.7)	18 (52.9)	147 (49.7)	83 (55.3)	811 (47.3)
Not married	205 (66.3)	38 (41.8)	91 (31.2)	336 (61.8)	16 (47.1)	149 (50.3)	67 (44.7)	902 (52.6)
Residency ^C								
Urban	183 (59.2)	84 (92.3)	185 (63.4)	320 (58.8)	21 (61.8)	81 (27.4)	102 (68.0)	976 (56.9)
Rural	126 (40.8)	7 (7.7)	107 (36.6)	224 (41.2)	13 (38.2)	215 (72.6)	48 (32.0)	740 (43.1)
HIV ^D								
HIV-/not known	262 (84.8)	89 (97.8)	286 (97.9)	400 (73.5)	31 (91.2)	263 (88.9)	127 (84.7)	1458 (85.0)
HIV +	47 (15.2)	2 (2.2)	6 (2.1)	144 (26.5)	3 (8.8)	33 (11.1)	23 (15.3)	258 (15.0)
Pre-existing non-HIV comorbidities ^E								
No	159 (51.5)	32 (35.2)	67 (22.9)	224 (41.2)	12 (35.3)	204 (68.9)	92 (61.4)	790 (46.1)
Minor problems	103 (33.3)	35 (38.5)	139 (47.6)	114 (21.0)	9 (26.5)	72 (24.3)	50 (33.3)	522 (30.4)
Major Problems	47 (15.2)	24 (26.4)	86 (29.5)	110 (20.2)	7 (20.6)	20 (6.8)	8 (5.3)	302 (17.6)
missing	0 (0.0)	0 (0.0)	0 (0.0)	96 (17.6)	6 (17.6)	0 (0.0)	0 (0.0)	102 (5.9)
BMI (kg/m ²)								
<18.5	29 (9.4)	2 (2.2)	12 (4.1)	8 (1.5)	2 (5.9)	7 (2.4)	5 (3.3)	65 (3.8)
18.5 to <25	106 (34.3)	28 (30.8)	109 (37.3)	101 (18.6)	7 (20.6)	122 (41.2)	53 (35.4)	526 (30.6)
25 to <30	80 (25.9)	18 (19.8)	86 (29.5)	107 (19.7)	10 (29.4)	118 (39.9)	41 (27.3)	460 (26.8)
≥ 30	85 (27.5)	39 (42.8)	74 (25.3)	295 (54.2)	10 (29.4)	44 (14.9)	36 (24.0)	583 (34.0)
missing	9 (2.9)	4 (4.4)	11 (3.8)	33 (6.0)	5 (14.7)	5 (1.7)	15 (10.0)	82 (4.8)
Menopausal status								
Post	147 (47.6)	66 (72.5)	146 (50.0)	317 (58.3)	21 (61.8)	131 (44.3)	79 (52.7)	907 (52.9)
Pre	162 (52.4)	25 (27.5)	146 (50.0)	218 (40.1)	13 (38.2)	165 (55.7)	71 (47.3)	800 (46.6)
NA ^F	0 (0.0)	0 (0.0)	0 (0.0)	9 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	9 (0.5)

^A Based on a score ranging from 0 (low) to 9 (high) was generated from the sum of 9 equally-weighted (+1 each) possessions: home ownership; indoor water; flush toilet; electricity; vehicle; refrigerator; landline phone; gas or electric stove; and a bed; ^B Three missing values in South Africa non-black women; ^C Usual place of residence was defined as urban (city/town) or rural (village/rural) in ABC-DO and, in Soweto, as residing <10 km or ≥10 km straight-line distance to the hospital; ^D HIV-status self-reported except of systematic patient testing in South Africa.

^E The non-HIV comorbidities tuberculosis, hypertension, heart disease, anaemia, diabetes, COPD, hepatitis, asthma, other cancer and other infection were assessed one by one in ABC-DO and categorized, in line with the Soweto data, to perfect health (no comorbidity), minor problems (1 comorbidity) and major problems (>1 comorbidity); ^F Patient after hysterectomy;

Supplementary Table 3: Tumour profile at presentation in non-metastatic women with known TNM stage information in the prospective African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort, by patient group

	Namibia black	Namibia non-black	Nigeria	SA black	SA non-black	Uganda	Zambia	Total
N	309	91	292	544	34	296	150	1716
Stage category^A	N (column %)							
Localised BC	178 (57.6)	75 (82.4)	127 (43.5)	344 (63.2)	26 (76.5)	191 (64.5)	87 (58.0)	1028 (59.9)
Locally advanced BC	131 (42.4)	16 (17.6)	165 (56.5)	200 (36.8)	8 (23.5)	105 (35.5)	63 (42.0)	688 (40.1)
Nodes^B								
N0 (0)	38 (40.0)	24 (63.2)	58 (34.7)	107 (35.4)	7 (36.8)	52 (28.3)	27 (41.5)	313 (36.0)
N1 (1-3)	24 (25.3)	11 (28.9)	63 (37.7)	94 (31.1)	7 (36.8)	115 (62.5)	24 (36.9)	338 (38.9)
N2 (4-9)	25 (26.3)	2 (5.3)	36 (21.6)	39 (12.9)	0 (0.0)	7 (3.8)	5 (7.7)	114 (13.1)
N3 (10+)	8 (8.4)	1 (2.6)	6 (3.6)	15 (5.0)	4 (21.1)	1 (0.5)	4 (6.2)	39 (4.5)
missing	0 (0.0)	0 (0.0)	4 (2.4)	47 (15.6)	1 (5.3)	9 (4.9)	5 (7.7)	66 (7.5)
Tumour Size								
≤ 2cm	21 (6.8)	25 (27.5)	11 (3.8)	91 (16.7)	7 (20.6)	27 (9.1)	10 (6.7)	192 (11.1)
2- ≤ 5cm	97 (31.4)	39 (42.9)	70 (24.0)	265 (48.7)	17 (50.0)	130 (43.9)	49 (32.7)	667 (38.9)
5cm+	190 (61.5)	27 (29.6)	156 (53.4)	112 (20.6)	6 (17.6)	102 (34.5)	64 (42.6)	657 (38.3)
missing	1 (0.3)	0 (0.0)	55 (18.8)	76 (14.0)	4 (11.8)	37 (12.5)	27 (18.0)	200 (11.7)
Grade / Differentiation								
Well	46 (14.9)	24 (26.4)	6 (2.1)	36 (6.6)	1 (2.9)	59 (19.9)	13 (8.7)	185 (10.8)
Moderately	113 (36.6)	31 (34.1)	24 (8.2)	275 (50.6)	22 (64.7)	59 (19.9)	45 (30.0)	569 (33.2)
Poorly	67 (21.6)	22 (24.1)	3 (1.0)	217 (39.9)	11 (32.4)	64 (21.7)	25 (16.6)	409 (23.8)
Unable to determine	83 (26.9)	14 (15.4)	162 (55.5)	0 (0.0)	0 (0.0)	111 (37.5)	63 (42.0)	433 (25.2)
Missing	0 (0.0)	0 (0.0)	97 (33.2)	16 (2.9)	0 (0.0)	3 (1.0)	4 (2.7)	120 (7.0)
Hormone receptors								
Positive	223 (72.2)	71 (78.0)	23 (7.9)	428 (78.7)	31 (91.2)	25 (8.4)	27 (18.0)	828 (48.2)
Negative	79 (25.5)	19 (20.9)	13 (4.5)	114 (21.0)	3 (8.8)	13 (4.4)	16 (10.7)	257 (15.0)
Unknown	7 (2.3)	1 (1.1)	256 (87.6)	2 (0.3)	0 (0.0)	258 (87.2)	107 (71.3)	631 (36.8)
HER2								
Negative	199 (64.4)	70 (76.9)	35 (12.0)	302 (55.5)	23 (67.6)	30 (10.2)	33 (22.0)	692 (40.4)
Positive	99 (32.0)	18 (19.8)	4 (1.4)	118 (21.7)	7 (20.6)	6 (2.0)	6 (4.0)	258 (15.0)
missing	11 (3.6)	3 (3.3)	253 (86.6)	124 (22.8)	4 (11.8)	260 (87.8)	111 (74.0)	766 (44.6)
Molecular subtype^C								
HR+/HER-	147 (47.6)	55 (60.4)	20 (6.8)	301 (55.4)	23 (67.6)	20 (6.8)	23 (15.3)	589 (34.3)
HR+/HER+	74 (23.9)	14 (15.4)	3 (1.0)	114 (21.0)	8 (23.6)	3 (1.0)	3 (2.0)	219 (12.8)
HR-/HER2+	25 (8.1)	4 (4.4)	1 (0.3)	23 (4.2)	0 (0.0)	3 (1.0)	3 (2.0)	59 (3.4)
HR-/HER-	50 (16.2)	15 (16.5)	10 (3.4)	90 (16.5)	3 (8.8)	10 (3.4)	10 (6.7)	188 (11.0)
unknown	13 (4.2)	3 (3.3)	258 (88.5)	16 (2.9)	0 (0.0)	260 (87.8)	111 (74.0)	661 (38.5)

^A Dichotomized variable derived from tumour size, nodes and metastases to assess correlation with the NCCN guidelines. Localized T1-3,N0-1,M0 vs locally advanced/inoperable tumours T4,N2-3,M0;

^B Only reported for women not receiving neo-adjuvant treatment.

^C IHC testing was only routinely done in Namibia and South Africa. Information on IHC determined oestrogen (ER), progesterone (PR) and human epidermal growth factor 2 receptors (HER2) were extracted, the latter with florescent in-situ hybridization (FISH) for equivocal results. ER and PR were considered positive with >1% staining, and HER2+ if FISH was positive or the HER2 score was 3.

Supplementary Table 4: TNM staging and ascertainment of T, N and M in patients diagnosed with non-metastatic disease in the ABC-DO cohort

	Namibia black	Namibia non- black	Nigeria	South Africa black	South Africa mixed- race	Uganda	Zambia	Total
N	309	91	292	544	34	296	150	1716
	N (column %)							
TNM Stage								
I (T1N0M0, T0N1M0)	17 (6)	22 (24)	11 (4)	28 (5)	2 (6)	35 (12)	4 (3)	119 (7)
IIA (T0N1M0, T1N1M0, T2N0M0)	52 (17)	26 (29)	28 (10)	131 (24)	11 (32)	58 (20)	18 (12)	324 (19)
IIB (T2N1M0, T3N0M0)	64 (21)	25 (28)	50 (17)	138 (25)	9 (27)	49 (17)	50 (33)	385 (22)
IIIA (T0/T1/T2 N2M0, T3 N1/N2 M0)	84 (27)	6 (7)	66 (23)	96 (18)	6 (18)	54 (18)	19 (13)	331 (19)
IIIB (T4 N0/N1/N2 M0)	62 (20)	8 (9)	125 (43)	131 (24)	6 (18)	83 (28)	47 (31)	462 (27)
IIIC (T1-T4 N3 M0)	30 (10)	4 (4)	12 (4)	20 (4)	0 (0)	17 (6)	12 (8)	95 (6)
Ascertainment: Tumour size								
Clinical with imaging ^A	41 (13)	35 (39)	101 (35)	0 (0)	0 (0)	241 (81)	102 (68)	520 (30)
Clinical, detailed imaging unknown	176 (57)	25 (28)	180 (62)	544 (100)	34 (100)	41 (14)	24 (16)	1024 (60)
Pathological	91 (29)	31 (34)	6 (2)	0 (0)	0 (0)	4 (1)	6 (4)	138 (8)
Unknown/not assessed	1 (0)	0 (0)	5 (2)	0 (0)	0 (0)	10 (3)	18 (12)	34 (2)
Ascertainment: Nodes								
Clinical with imaging ^A	42 (14)	47 (52)	97 (33)	0 (0)	0 (0)	214 (72)	97 (65)	497 (29)
Clinical, detailed imaging unknown	197 (64)	26 (29)	190 (65)	544 (100)	34 (100)	69 (23)	28 (19)	1088 (63)
Pathological	70 (23)	18 (20)	0 (0)	0 (0)	0 (0)	7 (2)	4 (3)	99 (6)
Unknown/ not assessed	0 (0)	0 (0)	5 (2)	0 (0)	0 (0)	6 (2)	21 (14)	32 (2)
Methods of ascertainment of metastases								
Imaging ^B	282 (91)	84 (92)	103 (35)	544 (100)	34 (100)	146 (49)	108 (72)	1301 (76)
Clinically/Unknown	27 (9)	7 (8)	189 (65)	0 (0)	0 (0)	150 (51)	42 (28)	415 (24)

^A Mostly ultrasound and/or Mammography

^B Mostly ultrasound and/or Xray, additional CT scans in South Africa

Supplementary Table 5: Details of breast cancer surgical management in ABC-DO for patients receiving breast cancer surgery separately for localised tumours vs locally advanced tumours.


Group	Namibia black	Namibia non-black	Nigeria	South Africa black	South Africa mixed-race	Uganda	Zambia	Total
No. women.	309	91	292	544	34	296	150	1716
	N (column %)							
Localised BC^A	178/309 (58)	75/91 (82)	127/292 (43)	344/544 (63)	26/34 (76)	191/296 (65)	87/150 (58)	1028/1716 (60)
Surgery performed	144/178 (81)	69/75 (92%)	83/127 (65)	311/344 (90)	24/26 (92)	127/191 (66)	58/87 (67)	816/1028 (80)
Type								
Mastectomy	129/144 (90)	54/69 (78)	39/83 (47)	215/311 (69)	14/24 (58)	117/127 (92)	56/58 (97)	624/816 (77)
Of these, radiotherapy	98/129 (76)	33/54 (61)	4/39 (10)	77/215 (36)	9/14 (64)	37/117 (32)	26/56 (46)	426/624 (47)
Breast Conserving Surgery (BCS)	15/144 (10)	15/69 (22)	44/83 (53)	96/311 (31)	10/24 (42)	10/127 (8)	2/58 (3)	192/816 (24)
Of BCS, radiotherapy initiated	13/15 (87)	14/15 (93)	2/44 (5)	51/96 (53)	6/10 (60)	4/10 (40)	0/2 (0)	90/192 (47)
Lymph node dissection								
Not done	9/144 (6)	0/69 (0)	2/83 (2)	3/311 (1)	0/24 (0)	17/127 (13)	1/58 (2)	32/816 (4)
Sentinel or sampling	18/144 (13)	14/69 (20)	3/83 (4)	0/311 (0)	0/24 (0)	0/127 (0)	0/58 (0)	35/816 (4)
Complete axillary dissection	25/144 (17)	7/69 (10)	4/83 (5)	278/311 (89)	23/24 (96)	3/127 (2)	2/58 (3)	342/816 (42)
unknown	92/144 (64)	48/69 (70)	74/83 (89)	30/311 (10)	1/24 (4)	107/127 (84)	55/58 (95)	407/816 (50)
Additional systemic therapy ^B								
neoadjuvant	89/144 (62)	35/69 (51)	26/83 (31)	63/311 (20)	6/24 (25)	13/127 (10)	27/58 (47)	475/816 (41)
adjuvant	95/144 (66)	52/69 (75)	43/83 (52)	268/311 (86)	21/24 (88)	117/127 (92)	37/58 (64)	851/816 (73)
None	3/144 (2)	2/69 (3)	25/83 (30)	14/311 (5)	1/24 (4)	8/127 (6)	7/58 (12)	60/816 (7)
Locally advanced^A	131/309 (42)	16/91 (18)	165/292 (57)	200/544 (37)	8/34 (24)	106/296 (35)	63/150 (42)	689/1716 (40)
Surgery performed	77/131 (59)	13/16 (81)	73/165 (44)	105/200 (53)	4/8 (50)	55/106 (52)	21/63 (33)	348/689 (51)
Type								
Mastectomy	76/77 (99)	12/13 (92)	41/73 (56)	82/105 (78)	4/4 (100)	50/55 (91)	20/21 (95)	285/348 (82)
Of these, radiotherapy	62/76 (82)	10/12 (83)	3/41 (7)	50/82 (61)	3/4 (75)	8/50 (16)	6/20 (30)	0/285 (0)
BCS	1/77 (1)	1/13 (8)	32/73 (44)	23/105 (22)	0/4 (0)	5/55 (9)	1/21 (5)	63/348 (18)
Of BCS, radiotherapy initiated	0/1 (0)	1/1 (100)	0/32 (0)	16/23 (70)	0/0 (0)	0/5 (0)	0/1 (0)	17/63 (27)
Lymph node dissection								
Not done	2/77 (3)	0/13 (0)	2/73 (3)	3/105 (3)	0/4 (0)	6/55 (11)	0/21 (0)	13/348 (4)
Sentinel or sampling	8/77 (10)	1/13 (8)	0/73 (0)	0/105 (0)	0/4 (0)	0/55 (0)	0/21 (0)	9/348 (3)
Complete axillary dissection	15/77 (19)	4/13 (31)	2/73 (3)	84/105 (80)	3/4 (75)	5/55 (9)	2/21 (10)	115/348 (33)
unknown	52/77 (68)	8/13 (62)	69/73 (95)	18/105 (17)	1/4 (25)	44/55 (80)	19/21 (90)	211/348 (61)
Additional systemic therapy ^C								
neoadjuvant	43/77 (56)	10/13 (77)	43/73 (59)	94/105 (90)	3/4 (75)	10/55 (18)	13/21 (62)	216/348 (62)
adjuvant	48/77 (62)	9/13 (69)	33/73 (45)	64/105 (61)	4/4 (100)	50/55 (91)	10/21 (48)	218/348 (63)
none	3/77 (4)	0/13 (0)	10/73 (14)	6/105 (6)	0/4 (0)	4/55 (7)	2/21 (10)	25/348 (7)

^A Dichotomized variable derived from tumour size, nodes and metastases to assess correlation with the NCCN guidelines. Localized T1-3,N0-1,M0 vs locally advanced/inoperable tumours T4,N2-3,M0.

^B Column percentage >100% due to 136 women receiving neoadjuvant and adjuvant systemic therapy

^C Column percentage >100% due to 111 women receiving neoadjuvant and adjuvant systemic therapy

Supplementary Figure 1: Venn diagrams of treatment initiated in the ABC-DO cohort for women presenting with localised (A) vs locally advanced (B) tumours.




Supplementary Figure 1, Input data


	Localised tumours (T1-3, N0-1, M0)	Locally advanced tumours (T4, N2-3, M0)
Treatment combination, Total number of women	1028	688
	N (column %)	N (column %)
No treatment	77 (7)	104 (15)
Surgery alone	56 (5)	22 (3)
Surgery & Chemotherapy	112 (11)	67 (10)
Surgery & endocrine therapy	85 (8)	11 (2)
Surgery, chemotherapy & endocrine therapy	189 (18)	89 (13)
Surgery & radiotherapy	4 (0)	3 (0)
Chemotherapy alone	40 (4)	140 (20)
Endocrine therapy alone	48 (5)	34 (5)
Chemotherapy and endocrine therapy	27 (3)	46 (7)
Chemotherapy & radiotherapy	3 (0)	3 (0)
Endocrine therapy & radiotherapy	2 (0)	0 (0)
Chemotherapy, endocrine therapy & radiotherapy	15 (1)	13 (2)
Surgery, chemotherapy and radiotherapy	70 (7)	41 (6)
Surgery, endocrine therapy and radiotherapy	33 (3)	5 (1)
Surgery, chemotherapy, endocrine therapy & radiotherapy	267 (26)	110 (16)

Supplementary Figure 2 A-C. Percentage of treatment indicated versus received for women with non-metastatic BC per population group in the ABC-DO cohort. The dominator of all bar heights is the N per population group. Percentages in brackets on the labels of lower bars correspond to the percentage of women initiating treatment amongst all eligible/indicated (the higher bar).


A) Surgery



B) Chemotherapy



C) Endocrine Therapy



Supplementary Figure 3: Breast cancer treatment timeline for 15 randomly selected women in each population group. (Zam: Zambia; Uga: Uganda; SA mr: South Africa mixed-race; SA bl: South Africa black; Nam nbl: Namibia non-black; Nam bl: Namibia black)

